The Series B announcement arrived with little fanfare—a LinkedIn post in late July, not even a formal press release. But the numbers told a different story: over $200 million raised at a $2 billion valuation for Simile, a Palo Alto startup that's betting enterprises will pay handsomely to predict how real people behave before making costly decisions.
Greenoaks and Index Ventures co-led the round, with a roster of participants that included Hanabi Capital, A* Capital, Bain Capital Ventures, CVS Health Ventures, and Definition, according to the company and data from Dealroom.co. The deal came just five and a half months after Simile emerged from stealth with a $100 million Series A—led by Index—that drew backing from AI luminaries including Fei-Fei Li, Andrej Karpathy, and Adam D'Angelo.
Five months. That's an unusually compressed timeline between institutional funding rounds, even in an AI market known for moving fast and writing large checks. Index's decision to co-lead the B round after anchoring the A speaks to either remarkable traction or remarkable conviction. Possibly both.
Simulations at Scale
Simile builds what it calls "agentic twins"—digital representations of individuals designed to forecast how real people might respond to new products, policy changes, or business decisions. It's a concept rooted in academic research on "generative agents," AI systems that simulate human behavior patterns at scale.
CEO Joon Sung Park, who co-founded the company with Stanford professors Michael Bernstein and Percy Liang alongside Elaina Yallen, authored influential research in this area. His work on creating interactive digital personas helped lay the intellectual foundation for Simile's commercial platform, which the company says has now run "tens of millions" of simulations for Fortune 100 clients.
The startup claimed 5x revenue growth during the five-month span between funding rounds. Absolute revenue figures? Those remain undisclosed. But the company's willingness to cite simulation volume alongside a growing roster of brand-name customers suggests it's found early product-market fit in a narrow but potentially lucrative niche.
Simile has scaled to more than 50 employees since its founding, according to the Series B announcement—a modest headcount for a company now valued at $2 billion, though perhaps appropriate for an enterprise software play still in its early commercial stages.
CVS and Beyond
CVS Health is one of Simile's prominent customers, with public case studies available. The healthcare giant went on record earlier describing how it uses Simile's platform to test patient experience improvements across more than 200 behavioral scenarios, drawing on what the company said was 2.9 million consented customer responses. The deployment allows CVS to simulate reactions before rolling out changes—essentially a digital focus group at unprecedented scale.
CVS Health Ventures' participation in the Series B isn't subtle. Strategic capital from a customer signals more than financial backing; it hints at deeper integration plans or at least a commitment to the platform's roadmap. Whether CVS sees Simile as a competitive advantage or simply a useful tool remains to be seen.
The company also named Wealthfront, Deloitte, and Gallup as customers, suggesting traction beyond healthcare. Financial services, consulting, polling—these are verticals where understanding human behavior translates directly to revenue or client value. Simile appears to be threading a needle: specific enough to be useful, general enough to expand.
The Behavioral Forecasting Bet
At its core, Simile is wagering that enterprises will pay to reduce uncertainty. Not eliminate it—these are simulations, after all, not crystal balls. But in a world where launching a new product or changing a policy can cost millions, the ability to stress-test decisions against realistic behavioral models has obvious appeal.
The technology isn't without questions. How accurately can an AI model predict individual behavior? What happens when the model encounters scenarios outside its training distribution? And perhaps more fundamentally, do enterprises trust these simulations enough to make high-stakes decisions based on them?
Simile's customer list suggests at least some organizations are willing to find out. Whether the platform becomes a category-defining product or a feature that larger software vendors eventually replicate depends on execution over the next 12 to 18 months.
What Comes Next
The company hasn't detailed how it plans to deploy the new capital. Scaling the sales team seems likely given the enterprise motion. Continued investment in research—keeping pace with the breakneck speed of AI development—is probably table stakes. Acquisitions? Less clear, though in an AI market defined by talent wars and technology tuck-ins, it wouldn't be surprising.
Index's 20x valuation step-up in five months is the kind of bet that makes or breaks venture track records. The firm clearly sees something others might be missing, or it's riding momentum in a market segment where behavioral AI is just beginning to find commercial applications.
For now, Simile remains in that liminal space between promising startup and proven platform. The capital gives it room to find out which one it becomes.
